Berlin - Delayed Quote EUR

Hims & Hers Health Inc (82W.BE)

29.08

-1.59

(-5.18%)

At close: April 30 at 9:52:06 PM GMT+2

Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'

Eli Lilly's CEO waved off the Novo Nordisk-CVS GLP-1 formulary deal as he focuses on the future of the company's obesity pipeline.

Yahoo Finance 9 hours ago

CVS

HIMS

NONOF
CVS posts Q1 earnings beat, raises full-year guidance

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare Advantage headwinds.

Yahoo Finance 15 hours ago

CVS

LLY

UNH
Hims & Hers Health (NYSE:HIMS) Surges 24% In One Week After Novo Nordisk Partnership

Hims & Hers Health (NYSE:HIMS) recently announced a partnership with Novo Nordisk to enhance obesity care access in the U.S., coinciding with a notable 24% increase in its stock price over the last week. This announcement adds weight to broader market trends during a period where the Dow Jones and S&P 500 extended their upward trajectory due to robust earnings reports from major tech firms like Microsoft and Meta. Both the collaboration and company outlook aligned well with these positive...

Simply Wall St. 10 hours ago

HIMS
Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity Lead

The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.

The Wall Street Journal yesterday

LLY

LFMD

LFMDP
Stock Bulls Fuel Best Winning Run Since March 2022: Markets Wrap

(Bloomberg) -- Wall Street traders are cautiously adding fuel to the stock rebound, in a high-stakes bet that Corporate America will weather slowing economic growth and tariff-fueled disruptions to earnings.Most Read from BloombergNew York City Transit System Chips Away at Subway Fare EvasionNYC’s Congestion Toll Raised $159 Million in the First QuarterThe Last Thing US Transit Agencies Should Do NowAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryAt the National Public Housing

Bloomberg 2 days ago

HON

V

PFE
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy

Hims stock launched Tuesday after the company inked a deal to offer Novo Nordisk's weight-loss drug, Wegovy, on its telehealth platform.

Investor's Business Daily 2 days ago

NONOF

NVO

HIMS
Hims-Novo Nordisk partnership, SoFi earnings, Spotify guidance

Yahoo Finance host Madison Mills tracks today's top moving stocks and biggest market stories in this Market Minute, including Hims & Hers Health's (HIMS) partnership with weight-loss drug manufacturer Novo Nordisk (NVO), SoFi Technologies (SOFI) after reporting first quarter earnings results, and music streamer Spotify's (SPOT) second quarter guidance for monthly active users (MAU). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Yahoo Finance Video 2 days ago

SOFI

HIMS

SPOT
Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership

Novo Nordisk launched access to its popular weight loss GLP-1 drug, Wegovy, through multiple telehealth platforms, including Hims & Hers.

Yahoo Finance 2 days ago

NONOF

NVO

LLY
Hims & Hers with Novo Nordisk, Hilton, PayPal: Trending Tickers

Morning Brief co-hosts Brad Smith and Madison Mills examine today's trending tickers. Hims & Hers (HIMS) partners with Novo Nordisk (NOVO-B.CO, NVO) to offer customers bundled weight-loss treatments. Hilton (HLT) reports strong earnings growth for the first quarter but lowered its full-year per-room sales forecast. PayPal (PYPL) announces mixed first quarter results, but reaffirms its outlook. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 2 days ago

HIMS

PYPL

HLT
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care

SAN FRANCISCO, April 29, 2025--Novo Nordisk and Hims & Hers Health, Inc. (NYSE: HIMS) today announced a long-term collaboration designed to make proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans.

Business Wire 2 days ago

HIMS
Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.

Yahoo Finance 6 days ago

NONOF

NVO

HIMS
Eli Lilly stock soars on positive weight-loss pill results

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & Hers Health (HIMS) stocks are falling on the news. Yahoo Finance Senior Healthcare Reporter Anjalee Khemlani joins Morning Brief to break down the details. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

Yahoo Finance Video 14 days ago

HIMS

LLY

NONOF
April 2025's Top Growth Stocks With Strong Insider Confidence

The United States market has shown a robust performance recently, climbing 8.4% in the last week and increasing by 5.9% over the past year, with earnings anticipated to grow by 13% annually. In this favorable environment, growth companies with high insider ownership can be particularly attractive as they often signal strong internal confidence and alignment of interests between management and shareholders.

Simply Wall St. 15 days ago

JEF

BILI

BLBLF
Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

SAN FRANCISCO, April 14, 2025--Hims & Hers Health, Inc. ("Hims & Hers", NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.

Business Wire 17 days ago

HIMS
Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings

Hims & Hers Health (NYSE:HIMS) recently experienced a 5% price increase over the past quarter, marked by significant corporate events. The company was added to the S&P 400 index and simultaneously dropped from the S&P 600, highlighting a shift in its market positioning. Alongside this, its focus on strategic acquisitions, as indicated by the pursuit of lab diagnostic facilities, aligns with its growth strategy. Despite the market facing a 6% decline due to global trade tensions, Hims & Hers...

Simply Wall St. 27 days ago

HIMS
Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let’s look at key 2024 data on HIMS to understand why investors and ana

TipRanks 28 days ago

HIMS
Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.

Investor's Business Daily 29 days ago

LLY

NONOF

NVO
Who Should Pay for Ozempic Is the Next Big Workplace Fight

Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.

The Wall Street Journal 30 days ago

HIMS
Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

Hims & Hers Health said it is expanding its weight-loss offerings with the addition of Eli Lilly & Co. Zepbound and generic liraglutide. The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs. “We’ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,” the company said.

The Wall Street Journal 30 days ago

LLY

HIMS
Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.

Yahoo Finance Video 30 days ago

JNJ

LLY

HIMS

Performance Overview

Return	82W.BE	S&P 500 (^GSPC)
YTD	+15.86%	-4.72%
1-Year	+148.97%	+11.67%
3-Year	+625.19%	+35.63%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Hims & Hers Health Inc (82W.BE)

Eli Lilly CEO waves off CVS-Novo Nordisk deal: 'It feels a little like last decade'

CVS posts Q1 earnings beat, raises full-year guidance

Hims & Hers Health (NYSE:HIMS) Surges 24% In One Week After Novo Nordisk Partnership

Why New Wegovy Deals Won’t Restore Novo Nordisk’s Obesity Lead

Stock Bulls Fuel Best Winning Run Since March 2022: Markets Wrap

Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy

Hims-Novo Nordisk partnership, SoFi earnings, Spotify guidance

Hims & Hers stock jumps on Novo Nordisk GLP-1 partnership

Hims & Hers with Novo Nordisk, Hilton, PayPal: Trending Tickers

Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care

Novo Nordisk wins case to kick knockoff Ozempic off the market, but it may not last

Eli Lilly stock soars on positive weight-loss pill results

April 2025's Top Growth Stocks With Strong Insider Confidence

Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

Hims & Hers Health (NYSE:HIMS) Rises 5% Over Last Quarter Following Strong 2024 Earnings

Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty

Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch

Who Should Pay for Ozempic Is the Next Big Workplace Fight

Hims & Hers Expands Weight Loss Offering, Adds Lilly’s Zepbound to Platform

Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback

Performance Overview